Because of increased incidence of MDR-tuberculosis new antitubercular drugs need to be developed. We conducted study to see role of ciprofloxacin as antitubercular drug
100 freshly diagnosed sputum smear positive cases were randomly allocated into two groups of 50 patients each. Group A received RHZE cipro daily for first 2 months followed by RH daily for next 4 months.In Group B ciprofloxacin was omitted from above regimen. Results were analysed in terms of bacteriological, radiological and clinical criteria after 15, 30, 45 days, 2, 4, and 6 months of chemotherapy.
In Group A 33 (66%), 45 (90%), 47 (94%) and 49 (98%) patients were sputum smear negative for acid fast bacilli after 15, 30, 45 days & 2 months of chemotherapy. The corresponding figure for Group B were 22 (44%), 36 (72%), 40 (80%) and 42 (84%) after 15, 30, 45 days, and 2 months of chemotherapy. The difference was statistically significant. Statistically there was no significant difference in sputum status among both the groups after 6 months of chemotherapy. Radiologically no difference was observed between two groups. In terms of clinical improvement in Group A showed significant improvement in relation to cough with expectoration and fever during first two months, but was leveled at 6 months. No significant difference among both the groups regarding adverse effects.CONCLUSIONS: Ciprofloxacin was found to have anti tubercular activity and resulted in faster sputum conversion rates after 15 days, 30 days, 45 days, and 2 months of chemotherapy.
Ciprofloxacin can be used as an useful adjunct to the antitubercular drugs in areas of high prevalence of drug resistance in intensive phase and also in drug resistant cases.
J. Kishan, None.